EPS

Goosehead Insurance posts strong 16% revenue growth but lower net income, betting big on its new digital platform and AI to justify heavy spending.

Amid market volatility, the S&P 500 firm reinforces its financial strength with a massive share repurchase program and its 34th year of dividend growth.

Universal Health Services will present at three key March conferences, facing investors with robust profits but also cautious analyst outlooks and industry challenges.

With strong 2025 results, packaging leader Ball Corp will address investors on its financial outlook and its central role in the sustainable materials market.

USANA posts higher 2025 sales fueled by its Hiya and Rise brands, but a Q4 loss and a shrinking core business reveal the high cost of its transformation.

As executives head to the BMO Global Metals Conference, Reliance navigates a mixed earnings report, industry consolidation, and a critical minerals boom.

The firm beat Q4 revenue guidance but faces a soft outlook, doubling down on a futuristic AI strategy and aggressive shareholder returns to navigate volatility.

Facing massive revenue declines and a shrinking coach network due to GLP-1 drugs, Medifast bets its future on a risky pivot from weight loss to metabolic health.

Following a year of robust earnings and a 10% dividend hike, Great-West Lifeco's CEO is set to detail the firm's future plans in a key investor chat.

Security giant Senstar finalizes its acquisition of 3D LiDAR innovator Blickfeld, a strategic move set to revolutionize security with smarter detection.

Hammond Power Solutions' C$365M acquisition of AEG Power Solutions transforms the transformer maker into a global force in industrial power electronics.

As Revvity execs prepare for key conferences, investors will watch for clues on AI strategy, growth guidance, and margin recovery after a mixed 2025.

With its burn treatment gaining traction and a pivotal wound care drug in late-stage trials, MediWound prepares to make its case to Wall Street.

Amidst a volatile stock history, GT Biopharma aims to secure vital funding for its innovative NK cell therapy pipeline at a key Toronto conference.

As Xtract One readies its Q2 results, investors eye its booming backlog against a backdrop of rising competition and ethical questions in AI security.

Forget simple indicators. A new breed of retail trader uses complex data, automation, and strict risk rules to gain a professional edge in the market.

With a bolstered cash runway from recent funding, Inventiva is all-in on its MASH drug, lanifibranor, racing against giants in a multi-billion dollar market.

Honeywell's $1.19 quarterly dividend highlights its robust financial health and commitment to shareholders, backed by a strong forecast for 2026.

Illinois Tool Works reaffirms its 'Dividend King' status with a new payout, signaling robust financial health and confidence in the industrial sector's recovery.

The Canadian restaurant giant defied a tough market in 2025, posting record sales and boosting investor payouts through strategic promotions and delivery.